AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21094572 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery (Control)
Number of subjects: 11
Study 19706190 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educators
Number of subjects: 135
Study 19706190 — intervention group
Group type: COMPARATOR
Intervention: Group members (not peer educators)
Number of subjects: 135
Study 17182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (25-100 mg)
Number of subjects: 61
Study 17182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (15-90 mg)
Number of subjects: 61
Study 17182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and nortriptyline
Number of subjects: 61
Study 17182183 — intervention group
Group type: COMPARATOR
Intervention: Benztropine (active placebo, 0.25-1 mg)
Number of subjects: 61
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: Colombian antivenom (20 ml initial dose)
Number of subjects: 210
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: Colombian antivenom (< 70 ml initial dose)
Number of subjects: 210
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian antivenom
Number of subjects: 210
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: Colombian antivenom
Number of subjects: 210
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecuadorian antivenom
Number of subjects: 210
Study 15539665 — intervention group
Group type: EXPERIMENTAL
Intervention: All antivenoms
Number of subjects: 210
Study 11185630 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 160 mg
Number of subjects: 13
Study 11185630 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 13
Study 11185630 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 160 mg plus hydrochlorothiazide 25 mg
Number of subjects: 13
Study 9103344 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthroid
Number of subjects: 22
Study 9103344 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoxine (Levoxyl)
Number of subjects: 22
Study 9103344 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic levothyroxine sodium preparations
Number of subjects: 22
Study 9103344 — intervention group
Group type: COMPARATOR
Intervention: All products (Synthroid, Levoxine, and 2 generic preparations)
Number of subjects: 22
Study 1503098 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) at a dose of 3 megaunits three times a week intramuscularly for 1 year
Number of subjects: 45
Study 1503098 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study 6094423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 09‐0415, 1200 mg bd orally before and after challenge with rhinovirus type 9
Number of subjects: 0
Study 6094423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30892045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) for 8 weeks
Number of subjects: 0
Study 28731882 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for preventing osteoporosis (n = 26)
Number of subjects: 51
Study 28731882 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise (exercise placebo intervention) (n = 25)
Number of subjects: 51
Study 28731882 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for preventing osteoporosis
Number of subjects: 51
Study 28731882 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise (exercise placebo intervention)
Number of subjects: 51
Study 26873954 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with stent retrievers
Number of subjects: 5
Study 26873954 — intervention group
Group type: COMPARATOR
Intervention: Standard care (including IV thrombolysis)
Number of subjects: 5
Study 25559798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm A)
Number of subjects: 138
Study 25559798 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 7.5 mg (arm B)
Number of subjects: 138
Study 25559798 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 12.5 mg (arm C)
Number of subjects: 138
Study 21885210 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic release methylphenidate (OROS-MPH)
Number of subjects: 303
Study 21885210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 303
Study 21885210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 21885210 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with MDD
Number of subjects: 303
Study 20478360 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training for 15 weeks, 30 sessions of 22 min each
Number of subjects: 27
Study 20478360 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback
Number of subjects: 27
Study 18771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of placenta growth factor (PLGF) at baseline and follow-up
Number of subjects: 704
Study 18771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of inhibin A at follow-up
Number of subjects: 704
Study 18771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of soluble fms‐like tyrosine kinase‐1 (sFlt‐1) at follow-up
Number of subjects: 704
Study 18771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in markers from baseline to follow-up
Number of subjects: 704
Study 18771979 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline markers for PE less than 27 weeks
Number of subjects: 704
Study 15878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-based timing tasks
Number of subjects: 0
Study 15878729 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent timing tasks
Number of subjects: 0
Study 15878729 — intervention group
Group type: COMPARATOR
Intervention: Control group performance
Number of subjects: 0
Study 12631397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 280
Study 12631397 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 280
Study 12631397 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 280
Study 12631397 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 280
Study 10536556 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9487 (1.5 mg kg‐1 initial dose followed by three repeat doses or a 30‐min infusion)
Number of subjects: 0
Study 10536556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (two incremental doses)
Number of subjects: 0
Study 10536556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine administration after Org 9487
Number of subjects: 0
Study 8911197 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Sprotte pencil-point-tip needles
Number of subjects: 138
Study 8911197 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge Quinke bevel-tip end-hole needles
Number of subjects: 138
Study 8911197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gertie Marx pencil-point-tip needles
Number of subjects: 138
Study 1909471 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 904
Study 367024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted heparin 5 000 IU/ml
Number of subjects: 167
Study 367024 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated heparin 25 000 IU/ml
Number of subjects: 167
Study 367024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 167
Study 31702876 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 3014
Study 31702876 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent live attenuated influenza vaccine (TLAIV)
Number of subjects: 3014
Study 31702876 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 3014
Study 31373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway to Health Program
Number of subjects: 0
Study 28372682 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet group (20 patients)
Number of subjects: 40
Study 28372682 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 40
Study 25708453 — intervention group
Group type: COMPARATOR
Intervention: Experience Corps(®) program (EC); high intensity (>15 h per week) involvement of older adult volunteers in schools.
Number of subjects: 0
Study 23850035 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical training for intrapartum emergencies
Number of subjects: 140
Study 23850035 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual training
Number of subjects: 140
Study 21808077 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaction condition
Number of subjects: 0
Study 21808077 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive condition
Number of subjects: 0
Study 21808077 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive condition
Number of subjects: 0
Study 21808077 — intervention group
Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 0
Study 19821984 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help problem-solving therapy
Number of subjects: 0
Study 19821984 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 15729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract (900 mg/day)
Number of subjects: 135
Study 15729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 135
Study 15729083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 12660503 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney recipients receiving oral prednisone (20 patients)
Number of subjects: 34
Study 12660503 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver recipients receiving oral prednisone (6 patients)
Number of subjects: 34
Study 12660503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recipients receiving ketoconazole and CsA or tacrolimus (8 patients)
Number of subjects: 34
Study 12660503 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 34
Study 10202365 — intervention group
Group type: EXPERIMENTAL
Intervention: CMPA children under age 3 years
Number of subjects: 0
Study 10202365 — intervention group
Group type: EXPERIMENTAL
Intervention: CMPA children over age 9 years
Number of subjects: 0
Study 10202365 — intervention group
Group type: COMPARATOR
Intervention: Children who lost sensitivity to milk
Number of subjects: 0
Study 7786927 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 0
Study 7786927 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 0
Study 7786927 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2243846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silver nitrate (Ag)
Number of subjects: 52
Study 2243846 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (1 gm/liter) plus bacitracin (50,000 units/liter) (NB)
Number of subjects: 52
Study 2243846 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 52
Study 580598 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Number of subjects: 72
Study 580598 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with total body irradiation (TBI)
Number of subjects: 72
Study 30458737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Number of subjects: 0
Study 30458737 — intervention group
Group type: COMPARATOR
Intervention: Lexia Reading (active-control group)
Number of subjects: 0
Study 27473046 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 43
Study 27473046 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 43
Study 25266443 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) and leucovorin (LV) as bolus injections (Mayo or modified Mayo) or bi-monthly with bolus and continuous infusion (LV5FU2 or simplified LV5FU2)
Number of subjects: 1033
Study 22705346 — intervention group
Group type: COMPARATOR
Intervention: Ready-made spectacles (RMS)
Number of subjects: 363
Study 22705346 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom spectacles (CS)
Number of subjects: 363
Study 19889189 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 15
Study 19889189 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 15
Study 18762597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram-based medication instruction sheets
Number of subjects: 245
Study 18762597 — intervention group
Group type: COMPARATOR
Intervention: Standard medication counseling
Number of subjects: 245
Study 16253150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari PEP device
Number of subjects: 8
Study 16253150 — intervention group
Group type: COMPARATOR
Intervention: No PEP (low-resistance Pari filter)
Number of subjects: 8
Study 12115793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) using interstitial high-dose-rate brachytherapy (HDR-BT) of 7 x 4.33 Gy (n = 8) and 7 x 5.2 Gy (n = 37)
Number of subjects: 45
Study 12115793 — intervention group
Group type: COMPARATOR
Intervention: Whole breast radiotherapy (WBRT) of 50 Gy (n = 63)
Number of subjects: 45
Study 12115793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) of 7 x 5.2 Gy HDR-BT (n = 46)
Number of subjects: 45
Study 12115793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor bed radiotherapy (TBRT) of 50-Gy wide-field electron irradiation (n = 17)
Number of subjects: 45
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with physiologic (75 mIU/mL) FSH
Number of subjects: 21
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with supraphysiologic (7,500 mIU/mL) FSH
Number of subjects: 21
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with FSH alone
Number of subjects: 21
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with hCG alone
Number of subjects: 21
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium with FBS supplemented with FSH with LH
Number of subjects: 21
Study 9935117 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture medium without FBS supplemented with physiologic FSH with LH
Number of subjects: 21
Study 9935117 — intervention group
Group type: COMPARATOR
Intervention: Culture medium without FBS supplemented with both concentrations of FSH alone and hCG alone
Number of subjects: 21
Study 9935117 — intervention group
Group type: COMPARATOR
Intervention: Culture medium without FBS with both concentrations of FSH alone
Number of subjects: 21
Study 9935117 — intervention group
Group type: COMPARATOR
Intervention: Culture medium without FBS with hCG alone
Number of subjects: 21
Study 9935117 — intervention group
Group type: COMPARATOR
Intervention: Culture medium without FBS with FSH with LH
Number of subjects: 21
Study 8688926 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative Treatment Planning (NTP)
Number of subjects: 16
Study 8688926 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Feedback System (CFS)
Number of subjects: 16
Study 8688926 — intervention group
Group type: COMPARATOR
Intervention: Experimental groups (NTP and CFS)
Number of subjects: 16
Study 2349366 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 18
Study 2349366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 447034 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13
Study 447034 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin A1
Number of subjects: 13
Study 30997657 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60
Study 30997657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit G
Number of subjects: 60
Study 30997657 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafil-G
Number of subjects: 60
Study 30997657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dia-Temp
Number of subjects: 60
Study 28864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1421
Study 28864322 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1421
Study 26039212 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-depleted haploidentical transplantation followed by infusion of genetically modified donor T cells (TK007 study)
Number of subjects: 0
Study 26039212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD with unmanipulated PBSCs from haploidentical family donors (TrRaMM study)
Number of subjects: 0
Study 22915288 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant human GH)
Number of subjects: 136
Study 20650652 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus cooking and exercise classes
Number of subjects: 40
Study 20650652 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study 20650652 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management questionnaire (experimental group)
Number of subjects: 40
Study 20650652 — intervention group
Group type: COMPARATOR
Intervention: Self-management questionnaire (control group)
Number of subjects: 40
Study 19812228 — intervention group
Group type: COMPARATOR
Intervention: MTX (Methotrexate)
Number of subjects: 0
Study 19812228 — intervention group
Group type: COMPARATOR
Intervention: TNFi+MTX (TNF inhibitors combined with Methotrexate)
Number of subjects: 0
Study 17101908 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 26
Study 14633531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interscalene block with 30 mL of 0.5% levobupivacaine
Number of subjects: 102
Study 14633531 — intervention group
Group type: COMPARATOR
Intervention: Postoperative interscalene block with 30 mL of 0.5% levobupivacaine
Number of subjects: 102
Study 10975586 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 (25, 50, or 100 mg, i.v.)
Number of subjects: 24
Study 9394260 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy programs for depression
Number of subjects: 0
Study 9394260 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptomatology
Number of subjects: 0
Study 1300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical esophago-gastrostomy (CA)
Number of subjects: 60
Study 1300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic esophago-gastrostomy (TA)
Number of subjects: 60
Study 1300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal esophagectomy
Number of subjects: 60
Study 1300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 60
Study 3158620 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 2% zinc sulfate solution
Number of subjects: 30
Study 3158620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31063000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (SE)
Number of subjects: 111
Study 31063000 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 111
Study 31063000 — intervention group
Group type: COMPARATOR
Intervention: Treadmill testing
Number of subjects: 111
Study 29852804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided percutaneous A1 pulley release
Number of subjects: 41
Study 29852804 — intervention group
Group type: COMPARATOR
Intervention: Blind percutaneous A1 pulley release
Number of subjects: 41
Study 26293542 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Enhancement and Activation Program (12 weeks)
Number of subjects: 64
Study 24302681 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (400 mg)
Number of subjects: 45
Study 24302681 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (400 mg)
Number of subjects: 45
Study 24302681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23161039 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled time administration of Ketorolac (bolus after surgical incision and then every 8 hours for 24 hours)
Number of subjects: 80
Study 23161039 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of Ketorolac (2 ml/h for 24 hours)
Number of subjects: 80
Study 20832963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180‐mg loading dose, 90 mg twice daily)
Number of subjects: 69
Study 20832963 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300‐ to 600‐mg loading dose, 75 mg/day)
Number of subjects: 69
Study 20832963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Number of subjects: 69
Study 20832963 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel loading dose
Number of subjects: 69
Study 18158761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine-rich protein (IMN1207)
Number of subjects: 66
Study 18158761 — intervention group
Group type: COMPARATOR
Intervention: Casein (control)
Number of subjects: 66
Study 16015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage with 5 g beta-glucans from oats
Number of subjects: 100
Study 16015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage with 10 g beta-glucans from oats
Number of subjects: 100
Study 16015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverages with barley beta-glucans
Number of subjects: 100
Study 16015250 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 100
Study 11796602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal NOMV vaccine
Number of subjects: 42
Study 11796602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal and oropharyngeal NOMV vaccine
Number of subjects: 42